S1438
Sulindac sulfone
≥94% (HPLC), (solid or powder)
Synonim(y):
(Z)-5-Fluoro-2-methyl-1-[p-(methylsulfonyl)benzylidene]indene-3-acetic acid
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Wzór empiryczny (zapis Hilla):
C20H17FO4S
Numer CAS:
Masa cząsteczkowa:
372.41
Numer MDL:
Kod UNSPSC:
51111800
Identyfikator substancji w PubChem:
NACRES:
NA.77
Aby zapytać o ten produkt S1438, skontaktuj się z lokalnym biurem lub sprzedawcą firmy Merck. Skontaktuj się z zespołem ds. pomocy technicznej
Polecane produkty
Próba
≥94% (HPLC)
Formularz
(solid or powder)
kolor
, Light Yellow to Dark Yellow
rozpuszczalność
DMSO: >25 mg/mL
ethanol: 3 mg/mL (warm)
acetone: 5 mg (plus 0.1 ml)
inicjator
Merck & Co., Inc., Kenilworth, NJ, U.S.
ciąg SMILES
CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C\c3ccc(cc3)S(C)(=O)=O
InChI
1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9+
Klucz InChI
MVGSNCBCUWPVDA-RQZCQDPDSA-N
Zastosowanie
Human endothelial cells, HMEC-1 were treated with Sulindac sulfone and the effect on cell survival was studied by MTT assay.[1]
Działania biochem./fizjol.
Metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. Inhibits the development and induces regression of premalignant adenomatous polyps.
Sulindac sulfone is non-steroidal anti-inflammatory drug and an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells1,2 and reduces tumor burden in adenomatous polyposis patients.3
Cechy i korzyści
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Uwaga dotycząca przygotowania
Sulindac sulfone yields clear, light yellow to dark yellow solution in acetone at 50 mg/ml.
Ta strona może zawierać tekst przetłumaczony maszynowo.
Kod klasy składowania
11 - Combustible Solids
Klasa zagrożenia wodnego (WGK)
WGK 3
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Środki ochrony indywidualnej
Eyeshields, Gloves, type N95 (US)
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Jin Kyung Lee et al.
The Journal of pharmacology and experimental therapeutics, 334(2), 410-418 (2010-05-01)
Sulindac is a commonly used nonsteroidal anti-inflammatory drug. This study tested the hypothesis that sulindac-mediated drug-drug interactions and/or hepatotoxicity may be caused, in part, by inhibition of proteins responsible for the hepatic transport of drugs and/or bile acids by sulindac
Tien Hoang et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 1(3), 218-225 (2007-04-06)
The study was designed to evaluate the safety and efficacy of exisulind, a selective apoptotic antineoplastic drug, in combination with gemcitabine as second-line therapy in patients with progressing advanced non-small cell lung cancer. Patients whose disease progressed more than 3
Gregory A Masters et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 1(7), 673-678 (2007-04-06)
Carboplatin and gemcitabine are one standard regimen for patients with advanced non-small cell lung cancer (NSCLC). The oral proapoptotic agent exisulind is a cyclic guanosine monophosphate phosphodiesterase that increases apoptosis in vitro. We performed a phase II trial of carboplatin
Steven Attia et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 3(9), 1018-1025 (2008-09-02)
Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC). Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC. Chemotherapy-naive
Nis Giladi et al.
Expert opinion on investigational drugs, 19 Suppl 1, S117-S124 (2010-04-14)
The use of sulindac sulfone (SFN) for colorectal cancer (CRC) therapy is limited due to its toxicity. The present study was carried out to examine whether curcumin, a novel chemopreventive agent, can potentiate the effects of low dosages of SFN
Produkty
Discover Bioactive Small Molecules for Lipid Signaling Research
Active Filters
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej
